Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.Nivolumab (Opdivo, Bristol Myers Squibb), a PD-1 inhibitor, also demonstrated an acceptable safety profile.“Neoadjuvant chemoradiation therapy followed by surgery, or trimodality therapy, is a widely used standard of care for patients with resectable locally advanced esophageal or gastroesophageal junction cancer. However, the risk for recurrenceRead More

Share on facebook
Share on twitter
Share on linkedin